Current pharmaceutical design最新文献

{"title":"Nanoparticles as Novel Drug Delivery Systems for Cancer Treatment: Current Status and Future Perspectives.","authors":"Kai Bin Liew, Hiu Ching Phang, Vinie Ying Xuan Tan, Phei Er Kee, Long Chiau Ming, Palanirajan Vijayarajkumar Kumar, Siew-Keah Lee, A B M Helal Uddin, Ritu M Gilhotra, Arya Kadukkattil Ramanunny","doi":"10.2174/0113816128368718250320060346","DOIUrl":"https://doi.org/10.2174/0113816128368718250320060346","url":null,"abstract":"<p><p>Cancer continues to pose a significant global health challenge, demanding innovative therapeutic approaches to overcome the limitations of conventional treatments like chemotherapy and radiotherapy. Nanoparticles (NPs) have emerged as promising tools for cancer therapy due to their unique physicochemical properties that enable targeted drug delivery, reduced systemic toxicity, and enhanced therapeutic efficacy. This comprehensive review delves into the mechanisms of NP-based drug delivery, highlighting both passive and active targeting strategies. It categorizes and discusses diverse NP types, including polymeric, lipid-based, and metallic nanoparticles, emphasizing their applications in enhancing the bioavailability and specificity of anticancer agents. This review also explores the integration of advanced technologies, such as theranostics and artificial intelligence, to optimize NP design and functionality for personalized medicine. However, challenges remain, including issues related to toxicity, drug resistance, and manufacturing scalability. Addressing these barriers requires interdisciplinary research focused on developing stimuli-responsive NPs, improving biocompatibility, and incorporating multimodal therapeutic platforms. Although substantial progress has been made, this review is limited by the paucity of clinical trials validating NP efficacy and safety in diverse patient populations. Future endeavors should prioritize translational research to bridge the gap between preclinical innovations and clinical applications, ensuring that these transformative technologies benefit a broader spectrum of cancer patients. The review underscores the immense potential of NPs in redefining cancer treatment while advocating for sustained research to address existing limitations and unlock their full therapeutic promise.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143970261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrated Metabolomics and Proteomics to Decipher Simiao Pill Improving Lipid Homeostasis through PTGES3-mediated Arachidonic Acid Metabolism in AIA Model.","authors":"Ying Cai, Sifan Guo, Chunsheng Lin, Yan Wang, Chao Wang, Zhibo Wang, Dandan Xie, Yu Guan, Shi Qiu, Hui Dong, Aihua Zhang","doi":"10.2174/0113816128374077250410042947","DOIUrl":"https://doi.org/10.2174/0113816128374077250410042947","url":null,"abstract":"<p><strong>Background: </strong>Simiao Pill (SMP) has been demonstrated to suppress inflammation and modulate immune function, thereby influencing the onset and progression of rheumatoid arthritis (RA). Nonetheless, the specific molecular mechanisms and targets through which SMP mediates metabolic regulation and enhances immune function have yet to be fully elucidated.</p><p><strong>Objective: </strong>In this study, we employed an integrated approach combining the analysis of dysregulated metabolites and proteins to identify, screen, and validate the metabolic regulatory targets of SMP in adjuvant-induced arthritis (AIA) rats by using pseudotargeted metabolomics and 4D-DIA quantitative proteomics methodologies.</p><p><strong>Methods: </strong>An AIA rat model was developed, and SMP was administered to AIA rats. Subsequently, assessments were conducted on paw edema, arthritis scores, histopathological changes and IL-1 β content of inflammatory factors in AIA rats. UHPLC-QTOF-MS/MS was employed to analyze endogenous metabolites in the serum. Metabolic pathway and protein profile were performed on the biomarkers. The protein-lipidphenotype map for the SMP-treated rats was constructed and the primary target closely related to the metabolic regulation of SMP was further screened and verified.</p><p><strong>Results: </strong>Pseudotargeted metabolomics analysis revealed that SMP can mitigate the down-regulation of lipid levels in AIA rats. Pathway enrichment analysis identified arachidonic acid metabolism as the most significantly affected metabolic pathway and SMP was found to substantially ameliorate the dysregulation of this pathway in AIA rats. Subsequent protein profiling led to the identification of five key proteins, with noteworthy obvious corrective effects observed on Ptges3 and Alox15 due to SMP treatment. A comprehensive protein- lipid-phenotypic landscape of SMP-treated rats was analyzed for the specific molecular expressions associated with the arachidonic acid pathway. According to the correlation matrix of dysregulated metabolite/ protein, we found that Ptges3 was ranked as the primary target closely related to the metabolic regulation of SMP, a finding further validated through immunofluorescence staining in rat joint and synovial cells.</p><p><strong>Conclusion: </strong>Our study confirmed that SMP exerts an anti-arthritic effect by modulating the arachidonic acid metabolic network via the Ptges3 protein in rat joints and human rheumatoid arthritis synovial fibroblasts. This finding offers a novel mechanistic insight into the pharmacological action of SMP in adjuvant-induced arthritis (AIA) in rats. It informs future research on the therapeutic potential of SMP in rheumatoid arthritis (RA).</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143968841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mechanisms of a Patented Chinese Herbal Medicine for Treating Hypothyroidism in In Vitro Fertilization-Embryo Transfer: A Combination of Network Pharmacology, Molecular Docking, and Molecular Dynamics Simulation.","authors":"Chang Liu, Weihuan Hu, Tianyi Zhou, Jue Zhou, Fangfang Wang, Xiaoling Feng, Fan Qu","doi":"10.2174/0113816128364578250212094405","DOIUrl":"https://doi.org/10.2174/0113816128364578250212094405","url":null,"abstract":"<p><strong>Background: </strong>Qu's formula 6 (QUF6), a patented Chinese herbal medicine, is used to treat hypothyroidism in the context of in vitro fertilization-embryo transfer (IVF-ET). This research aims to identify the potential bioactive components and elucidate the underlying molecular mechanisms by which QUF6 cures hypothyroidism during IVF-ET.</p><p><strong>Material and methods: </strong>To find the active components of QUF6, the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) and relevant literature were searched. GeneCards and other resources were used to find the targets associated with hypothyroidism and IVF-ET. Using Cytoscape software, the network of interactions was created between the targets and components, the proteinprotein interaction (PPI) network was built, and significant targets were verified. Afterward, Gene Ontology (GO) enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were performed on crucial targets. Finally, molecular docking and dynamic modeling were carried out to analyze the essential components and core targets of QUF6.</p><p><strong>Results: </strong>By creating an interaction network, it was discovered that 92 active components in QUF6 can operate on 25 disease-related targets, with quercetin and other components playing important pharmacodynamic roles. Tumor necrosis factor (TNF), interleukin-6 (IL-6), interleukin-1B (IL-1B), apoptosis regulator Bcl-2 (BCL2), prostaglandin G/H synthase 2 (PTGS2), cellular tumor antigen p53 (TP53), and epidermal growth factor (EGF) were the main targets for the therapy of hypothyroidism. The KEGG pathway enrichment study identified 91 signaling pathways, whereas the GO enrichment analysis identified 1608 entries. Through molecular docking and MD simulations, stable binding was identified between the top five active constituents and the top seven potential targets.</p><p><strong>Conclusion: </strong>Quercetin, beta-sitosterol, kaempferol, 7-ketocholesterol, and rehmapicrogenin were determined to be the active ingredients in QUF6. The potential mechanism of action for QUF6 may involve modulation of TNF, IL6, IL1B, BCL2, PTSG2, TP53, and EGF to regulate oxidative stress levels, inflammation responses, and apoptosis processes associated with hypothyroidism during IVF-ET.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143972778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CP-MLR/PLS-guided Quantitative Structure-activity Relationship Study on the Derivatives of Benzimidazolone as H3-Antihistaminic Agents.","authors":"Smriti Sharma, Shahista Chauhan, Brij Kishore Sharma","doi":"10.2174/0113816128330939250313060926","DOIUrl":"https://doi.org/10.2174/0113816128330939250313060926","url":null,"abstract":"<p><strong>Background: </strong>The well-known histamine H3 receptor antagonists are based on an imidazole scaffold. However, the interaction between hepatic CYP450 and imidazole-based drugs leads to some side effects, such as low potential, physicochemical problems, etc. Therefore, another category of chemical class, benzimidazolone has been explored as an antihistaminic H3 agent.</p><p><strong>Objectives: </strong>In this study, the histamine H3 binding affinity of benzimidazolone derivatives has been quantitatively investigated using Dragon descriptors.</p><p><strong>Methods: </strong>The models were developed from statistically corroborated quantitative structure-activity relationship (QSAR) models that delivered rationales for the description of the binding affinity of benzimidazolonebased derivatives. In addition, the identified descriptors through CP-MLR analysis for the histamine H3 binding affinity highlighted the role of symmetry, atomic mass, information content, electrostaticity, rings in the structures, number of chlorine atoms (nCL), and average valence connectivity index chi-3 (X3Av).</p><p><strong>Results: </strong>The PLS assessment validated the power of CP-MLR-identified descriptors. The applicability domain suggested that the model fulfills the superior feature parameters with good fit and predictive power.</p><p><strong>Conclusion: </strong>All the compounds were found to be within the applicability domain of the recommended models.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143983343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nanocarriers and Nanomaterials in Dentistry: A Review on Common Dental Issues and their Management.","authors":"Shiv Kumar, Nitasha Chauhan, Shruti Chopra, Amit Bhatia","doi":"10.2174/0113816128361827250312053051","DOIUrl":"https://doi.org/10.2174/0113816128361827250312053051","url":null,"abstract":"<p><p>Nanomaterials offer significant potential for disease diagnosis and dental treatments due to their unique properties, such as a large surface area and nanoscale size. According to the World Health Organization, about 3.5 billion people worldwide regularly experience dental problems, which can cause significant suffering and disrupt the sufferer's everyday activities. Dental problems, such as dental caries (tooth decay), pulpitis (inflammation of the dental pulp), periodontal disease (gum disease), tooth fractures, and impacted wisdom teeth, necessitate a multidimensional approach, involving nanotechnology, dental materials, implants, etc., treating the underlying problem while providing symptomatic relief. This review discusses the role of nanotechnology in addressing major dental issues like dental caries, periodontal diseases, and tooth fractures. The collaborative endeavors of sophisticated nanomaterials facilitate their application in dental science, improving therapeutic efficacy and enhancing patient comfort and overall oral health.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143984818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Review on Synthetic PLGA Polymer Incorporated with Phytocompounds: Elucidating the Molecular Cascades for Osteoporosis Treatment.","authors":"Saranya Srinivasan, Ashwathi Vijayalekha, Ashok Kumar Pandurangan","doi":"10.2174/0113816128343852250311040459","DOIUrl":"https://doi.org/10.2174/0113816128343852250311040459","url":null,"abstract":"<p><p>Osteoporosis, a skeletal disorder marked by the disruption and degeneration of bone tissues, undermines the structural integrity of bones. Globally, one in three women and one in five men face osteoporotic fractures as a result, and the expenditure on treating osteoporotic fractures is projected to surpass $25 billion by 2025. In addition to conventional medications such as monoclonal antibodies and hormonal therapies, research endeavors into bone tissue engineering due to the adverse effects associated with the prolonged use of pharmaceutical medications have spurred researchers to explore natural therapeutic compounds as a potentially safer and efficacious approach to treat osteoporosis. PLGA [Poly (lactic-co-glycolic acid)] is a copolymer that has garnered attention as a foundational material in biomedical applications due to its biocompatibility, its capacity to modify surface properties, and its ability to enhance interactions with biological materials. When combined with phytocompounds, PLGA has been reported to improve stability and efficacy in treating osteoporotic disorders. Various classes of bio-active phyto-compounds, including terpenoids, phenolic acids, alkaloids, and other nitrogen-containing metabolites, are recognized for their ability to stimulate osteogenic activities in osteoporotic conditions. They exert their effects by modulating signaling cascades in conjunction with bone growth factors. In recent years, natural polymers derived from bio-active compounds have garnered growing interest owing to their wide-ranging applications in biomedicine. This review provides comprehensive insights into the role of phytocompounds in targeting genes involved in the bone regeneration process. Additionally, it highlights the potential of the synthetic polymer PLGA in improving treatments for osteoporotic conditions.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143968840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current Insights into Endometriosis: Hormonal Management, Clinical Outcomes, and Opportunities for Progress.","authors":"Marzieh Neykhonji, Abdulridha Mohammed Al-Asady, Amir Avan, Majid Khazaei, Seyed Mahdi Hassanian","doi":"10.2174/0113816128354055250312014359","DOIUrl":"https://doi.org/10.2174/0113816128354055250312014359","url":null,"abstract":"<p><strong>Introduction: </strong>Endometriosis, a prevalent women's health condition, is associated with persistent pelvic pain and infertility. Despite ongoing research, its precise disease mechanism remains elusive, impeding the discovery of a definitive cure. However, the progression of this disease is driven by three central factors, namely estrogen, progesterone, and inflammatory processes. The current work summarizes an evaluation of hormonal drug therapy in endometriosis, highlighting pathogenesis, clinical studies, and the anticipated role of AI in improving diagnostic accuracy and therapeutic results.</p><p><strong>Methods: </strong>Current information related to endometriosis and the application of AI in its diagnosis and treatment were evaluated through an in-depth literature search in the PubMed database and Google Scholar search engine.</p><p><strong>Results: </strong>The current treatment modalities for this disease encompass drug therapy and surgery. In line with key contributing factors, the first-line pharmaceutical treatment revolves around progestin therapy, which involves administration either alone or in combination with a small amount of estrogen. Each medication is linked to certain drawbacks, encompassing bone loss associated with progesterone-only therapy, considerable cost implications, and heightened risks of bleeding, spotting, and drug intolerance when utilizing combined progesterone-estrogen therapy.</p><p><strong>Conclusion: </strong>Many clinical studies on endometriosis are currently investigating the overall impact of the therapeutic approach involving progesterone-estrogen therapy with respect to the treatment of pelvic pain, health-related quality of life, cost-effectiveness, and tolerability. The rise of artificial intelligence and its advanced data processing capabilities present a promising opportunity to revolutionize endometriosis diagnosis and treatment by offering novel approaches.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143983885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metformin and its Nanoformulations in Cancer Prevention and Therapy.","authors":"Biswajit Banerjee, Sabyasachi Banerjee, Tripti Sharma, Bankim Chandra Nandy, Amit Kumar Nayak, Arijit Mondal","doi":"10.2174/0113816128367242250214052019","DOIUrl":"https://doi.org/10.2174/0113816128367242250214052019","url":null,"abstract":"<p><p>Currently, the resistance to antineoplastic drugs is an important critical challenge in managing several forms of cancers. An improved prognosis for cancer patients is often associated with increased cell death markers. The objective of the current review article was to discuss how metformin works at the molecular level to fight different types of cancer. This review also discussed the latest developments in metformin nanoformulations and their enhanced anticancer effects and the feasibility of using nanoformulation to deliver metformin with its limitations and challenges. In the current review article, we compiled previously reported studies on metformin's anticancer properties and nanoformulations by searching them in commonly used electronic databases such as Scopus, Google Scholar, PubMed, Medline, Science Direct, etc. In many research investigations, it has been reported that metformin (oral antidiabetic drug commonly employed in the clinical management of type 2 diabetes mellitus), can also help fight cancer by encouraging cell death, mostly through a process called apoptosis. Several previously reported investigations revealed that metformin and its nanoformulations are capable of showing significant anticancer activity against various carcinoma cell lines. From the reported literature, it has been found that there was prominent evidence for anticancer activity of metformin. In addition, a number of studies pointed out that metformin-loaded nanoformulations are capable of showing higher antitumor activity than free metformin, resulting in better efficacy in the therapeutic management of cancer. Metformin-loaded nanoformulations can be employed as potentially useful option for cancer treatment.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144062601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Potential Diagnostic Application of Artificial Intelligence in Breast Cancer.","authors":"Matineh Behzadi, Anahita Azinfar, Hawraa Ibrahim Alshakarchi, Yeganeh Khazaei, Ibrahim Saeed Gataa, Gordon A Ferns, Hamid Naderi, Amir Avan, Hamid Fiuji, Masoud Pezeshki Rad","doi":"10.2174/0113816128369168250311172823","DOIUrl":"https://doi.org/10.2174/0113816128369168250311172823","url":null,"abstract":"<p><p>Breast cancer poses a significant global health challenge, necessitating improved diagnostic and treatment strategies. This review explores the role of artificial intelligence (AI) in enhancing breast cancer pathology, emphasizing risk assessment, early detection, and analysis of histopathological and mammographic data. AI platforms show promise in predicting breast cancer risks and identifying tumors up to three years before clinical diagnosis. Deep learning techniques, particularly convolutional neural networks (CNNs), effectively classify cancer subtypes and grade tumor risk, achieving accuracy comparable to expert radiologists. Despite these advancements, challenges, such as the need for high-quality datasets and integration into clinical workflows, persist. Continued research on AI technologies is essential for advancing breast cancer detection and improving patient outcomes.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143972891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Steatotic Shadows: The Dark Link Between Metabolic Dysfunction-associated Steatotic Liver Disease and Cancer Risk.","authors":"Shakta Mani Satyam, Mohamed El-Tanani, Syed Arman Rabbani, Alaa A Aljabali, Yahia El-Tanani, Dimitrios Patoulias, Manfredi Rizzo","doi":"10.2174/0113816128366825250307043756","DOIUrl":"https://doi.org/10.2174/0113816128366825250307043756","url":null,"abstract":"<p><p>Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) has become a worldwide health crisis. In addition to its effects on liver function, MASLD intensely increases the risk of hepatocellular carcinoma (HCC) and a number of extrahepatic cancers, including breast, colorectal, and pancreatic cancers. This review explores the complex network of molecular pathways linking MASLD to cancer, emphasizing the involvement of oxidative stress, lipotoxicity, insulin resistance, chronic inflammation, and mitochondrial dysfunction. Genetic variations in important genes, including PNPLA3, TM6SF2, and MBOAT7, increase this risk by hastening the course of the disease and making a person more susceptible to cancer. By shedding light on these important pathways and genetic factors, this research not only advances knowledge of the relationship between MASLD and cancer but also opens the door for novel treatment approaches meant to reduce the risk of cancer in MASLD patients. Millions of people afflicted by this deadly but silent illness may benefit from novel therapies that target these fundamental systems.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143794754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}